CHOROIDAL NEOVASCULARIZATION
Clinical trials for CHOROIDAL NEOVASCULARIZATION explained in plain language.
Never miss a new study
Get alerted when new CHOROIDAL NEOVASCULARIZATION trials appear
Sign up with your email to follow new studies for CHOROIDAL NEOVASCULARIZATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug tiespectus takes on aflibercept in major wet AMD trial
Disease control Recruiting nowThis study tests a new medicine called tiespectus (EYE201) for wet age-related macular degeneration, a leading cause of vision loss. About 960 people will receive either tiespectus or the standard treatment aflibercept via eye injections. The goal is to see if tiespectus can impr…
Matched conditions: CHOROIDAL NEOVASCULARIZATION
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New eye injection could change treatment for wet AMD
Disease control Recruiting nowThis study tests a new drug called tiespectus (MK-8748) against the current standard treatment, aflibercept, for people with wet age-related macular degeneration (AMD). About 960 participants will receive injections into the eye and be followed for a year to see if tiespectus can…
Matched conditions: CHOROIDAL NEOVASCULARIZATION
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Eye fluid clues may predict who benefits from vision-saving injections
Knowledge-focused Recruiting nowThis study analyzes blood and aqueous humor (eye fluid) from 250 people with type 1 choroidal neovascularization—a cause of vision loss—and from controls without the condition. Researchers measure biomarker levels and check whether they correlate with how well patients respond to…
Matched conditions: CHOROIDAL NEOVASCULARIZATION
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC